SciClone Provides Update on the Timing of Filing Its 2012 Annual Report on Form 10-K

SciClone Provides Update on the Timing of Filing Its 2012 Annual Report on Form 
FOSTER CITY, CA -- (Marketwire) -- 03/14/13 --   As previously
reported on February 22, 2013, SciClone Pharmaceuticals, Inc.
(NASDAQ: SCLN) is restating its financial statements for fiscal year
2011 and the first three quarters of fiscal 2012. The Company is in
the process of completing the restatement of the financials and the
Company's Annual Report on Form 10-K for the fiscal year ended
December 31, 2012. As a result of the Company's ongoing processes,
today the Company announced that it is filing a Form 12b-25,
Notification of Late Filing, to inform the Securities and Exchange
Commission that it will not be able to file its 2012 10-K by the
prescribed due date of March 18, 2013 without unreasonable effort or
expense. The Form 12b-25 filing allows the Company up to an
additional 15 calendar days following the prescribed due date to
file. SciClone intends to file its 2012 Form 10-K as soon as
"We are continuing to work diligently to complete our 2012 10-K
filing as expeditiously as we can," said Gary Titus, SciClone Chief
Financial Officer. "We look forward to announcing our full-year 2012
financial results and to providing an update on our Company's
progress and strategies f
or 2013 and beyond to the investment
community promptly after this filing through a press release,
conference call and webcast, as is our customary practice. Our goal
is to complete all the work necessary to file our 2012 Form 10-K on
or before April 2, 2013."  
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a leading hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit  
Forward-Looking Statements This press release contains
forward-looking statements regarding expected financial results and
expectations. Readers are urged to consider statements that include
the words "may," "will," "would," "could," "should," "might,"
"believes," "estimates," "projects," "potential," "expects," "plans,"
"anticipates," "intends," "continues," "forecast," "designed,"
"goal," "unaudited," "approximately" or the negative of those words
or other comparable words to be uncertain and forward-looking. These
statements are subject to risks and uncertainties that are difficult
to predict and actual outcomes may differ materially. These include
risks and uncertainties relating to: changes in results that may
occur in completing the close of SciClone's consolidated financial
statements for fiscal year 2012, completing the audit of SciClone's
consolidated financial statements for fiscal year 2012 or completing
the restatement of SciClone's financial statements as referenced.
Please also refer to other risks and uncertainties described in
SciClone's filings with the SEC. All forward-looking statements are
based on information currently available to SciClone and SciClone
assumes no obligation to update any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus 
Chief Financial Officer 
Jane Green 
Press spacebar to pause and continue. Press esc to stop.